Attenuated parainfluenza virus (PIV) vaccines
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsBrian R. Murphy, Peter L. Collins, Mario H. Skiadopoulos
Life of this patent
Estimating the term…
Abstract
The invention provides isolated nucleic acids encoding recombinant genomes or antigenomes of Human Parainfluenza Viruses that are useful as vaccines. The recombinant genomes or antigenomes can be incorporated into expression vectors for production of recombinant viruses in vitro. The invention also provides recombinant Human Parainfluenza viruses having one or more mutations that attenuate replication of the virus in a host.
Claims2
An isolated infectious, attenuated parainfluenza virus that is obtained by expressing a polynucleotide sequence encoding a partial or complete human PIV genome or antigenome that encodes at least a nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P) and a large polymerase (L) protein of a human PIV and that includes at least one mutation at a position corresponding to a position in the genome of HPIV3 strain JS cp45 selected from the group consisting of Va196 of the N protein, Ser389 of the N protein, Ile96 of the C protein, Pro199 of the M protein, Ile420 of the F protein, Ala450 of the F protein, Val384 of the HN protein, nucleotide 23 of the 3′ leader sequence, nucleotide 24 of the 3′ leader sequence, nucleotide 28 of the 3′ leader sequence, nucleotide 45 of the 3′ leader sequence and nucleotide 62 in the N gene start sequence in a cell, wherein the human PIV genome or antigenome is a chimeric PIV genome or antigenome comprising a polynucleotide sequence of a background partial or complete PIV genome or antigenome and at least one heterologous PIV sequence selected from a human parainfluenza virus type 1 (HPIV 1) sequence, a human parainfluenza virus type 2 (HPIV 2) sequence, a human parainfluenza virus type 3 (HPIV 3) sequence, a bovine parainfluenza virus (BPIV) sequence or a murine parainfluenza virus (MPIV) sequence, wherein the genome or antigenome further includes a mutation at the amino acid corresponding to Phe456 of the L protein of wild-type HPIV3.
An isolated infectious, attenuated parainfluenza virus the comprises a genome or antigenome that encodes at least a nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P) and a large polymerase (L) protein of a human PIV and that includes a mutation at the amino acid corresponding to Phe456 of the L protein of wild-type HPIV3 and at least one mutation at a position corresponding to a position in the genome of HPIV3 strain JS cp45 selected from the group consisting of Va196 of the N protein, Ser389 of the N protein, 11e96 of the C protein, Pro199 of the M protein, Ile420 of the F protein, Ala450 of the F protein, Val384 of the HN protein, nucleotide 23 of the 3′ leader sequence, nucleotide 24 of the 3′ leader sequence, nucleotide 28 of the 3′ leader sequence, nucleotide 45 of the 3′ leader sequence and nucleotide 62 in the N gene start sequence.
Dependencies are inferred from the claim text.